Helminthiasis
diseaseOn this page
Summary
Helminthiasis (MONDO:0004664) is a disease (an umbrella term covering 22 Mondo subtypes) and 30 clinical trials. Top therapeutic interventions include albendazole, praziquantel, and diethylcarbamazine. A subtype of parasitic infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 22 Mondo subtypes
- Clinical trials: 30
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | helminthiasis |
| Mondo ID | MONDO:0004664 |
| EFO | EFO:1001342 |
| MeSH | D006373 |
| DOID | DOID:883 |
| ICD-10-CM | B65-B83 |
| NCIT | C84751 |
| SNOMED CT | 27601005 |
| UMLS | C0018889 |
| MedGen | 6765 |
| Is cancer (heuristic) | no |
Also known as: helminthiasis
Disease family
This is a subtype of parasitic infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis
Related subtypes (16): parasitic Ichthyosporea infectious disease, protozoa infectious disease, coccidioidomycosis, cryptococcosis, microsporidiosis, Strongylida infectious disease, distomatosis, parasitic myositis, demodicidosis, cutaneous larva migrans, amoebiasis due to Entamoeba histolytica, amoebiasis due to free-living amoebae, parasitic eye infection, parasitic intestinal disorder, parasitemia, parasitic skin disorder
Subtypes (22): acanthocephaliasis, heterophyiasis, metagonimiasis, fascioliasis, fasciolopsiasis, monieziasis, clonorchiasis, dicrocoeliasis, echinostomiasis, fascioloidiasis, gnathomiasis, hymenolepiasis, necatoriasis, Nematoda infectious disease, opisthorchiasis, paragonimiasis, trichostrongyloidiasis, schistosomiasis, filariasis, angiostrongyliasis, intestinal helminthiasis, Cestode infectious disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
14 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Albendazole | Approved (phase 4) |
| Bithionol | Approved (phase 4) |
| Diethylcarbamazine | Approved (phase 4) |
| Ivermectin | Approved (phase 4) |
| Levamisole | Approved (phase 4) |
| Mebendazole | Approved (phase 4) |
| Moxidectin | Approved (phase 4) |
| Niclosamide | Approved (phase 4) |
| Oxamniquine | Approved (phase 4) |
| Piperazine | Approved (phase 4) |
| Praziquantel | Approved (phase 4) |
| Pyrantel | Approved (phase 4) |
| Thiabendazole | Approved (phase 4) |
| Triclabendazole | Approved (phase 4) |
| Praziquantel, (R)- | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 30.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 20 |
| PHASE4 | 4 |
| PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01192802 | PHASE4 | COMPLETED | Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora |
| NCT01459146 | PHASE4 | UNKNOWN | Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana |
| NCT02385058 | PHASE4 | COMPLETED | Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population |
| NCT02397772 | PHASE4 | COMPLETED | Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya |
| NCT02725255 | PHASE2/PHASE3 | COMPLETED | Design and Clinical Evaluation of a School Meal With Deworming Properties |
| NCT03014167 | PHASE3 | COMPLETED | Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) |
| NCT02636803 | PHASE2 | WITHDRAWN | Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults |
| NCT04041453 | PHASE2 | COMPLETED | Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients |
| NCT01755637 | PHASE1 | COMPLETED | Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population |
| NCT03173742 | PHASE1 | COMPLETED | Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) |
| NCT00001230 | Not specified | RECRUITING | Host Response to Infection and Treatment in Filarial Diseases |
| NCT00001406 | Not specified | RECRUITING | Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia |
| NCT00004996 | Not specified | COMPLETED | Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections |
| NCT00130910 | Not specified | COMPLETED | Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation |
| NCT00367627 | Not specified | COMPLETED | Relative Efficacy of Two Regimens of Ante-helminthic Treatment |
| NCT00463593 | Not specified | COMPLETED | Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes |
| NCT00469495 | Not specified | COMPLETED | Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis |
| NCT00507221 | Not specified | COMPLETED | Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression |
| NCT00817713 | Not specified | TERMINATED | Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa? |
| NCT01271049 | Not specified | TERMINATED | An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths |
| NCT01308268 | Not specified | UNKNOWN | Management of Soil-transmitted Helminthiasis and Strongyloidiasis |
| NCT01368354 | Not specified | COMPLETED | Taenia Solium Control Case Study in Zambia |
| NCT02362932 | Not specified | COMPLETED | The Effect of an Urban Sanitation Intervention on Child Health |
| NCT02396407 | Not specified | COMPLETED | Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health |
| NCT02420574 | Not specified | COMPLETED | Assessment of Drug Efficacy of Local Albendazole |
| NCT04041427 | Not specified | COMPLETED | Urine Albendazole Levels for Coverage Assessment |
| NCT04227834 | Not specified | UNKNOWN | Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education |
| NCT04227925 | Not specified | COMPLETED | The Longevity of Trichuris Trichiura Colonization |
| NCT05048485 | Not specified | COMPLETED | Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets |
| NCT06497075 | Not specified | COMPLETED | Co-administration of IVM and ALB in School-based Deworming in Uganda |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ALBENDAZOLE | 4 | 15 |
| PRAZIQUANTEL | 4 | 2 |
| DIETHYLCARBAMAZINE | 4 | 1 |
| IVERMECTIN | 4 | 1 |
| MEBENDAZOLE | 4 | 1 |
| MEGLUMINE | 4 | 1 |
| ANTIMONY | 3 | 1 |
| QUINFAMIDE | 3 | 1 |
| OXFENDAZOLE | 2 | 1 |
| CHEMBL263291 | 0 | 4 |
| CHEMBL3264245 | 0 | 2 |
| CHEMBL4082099 | 0 | 1 |
| CHEMBL4788951 | 0 | 1 |